InvestorIdeas Adds Biotech Stocks to Directories

Biotech, Mining, Renewable Energy, Entertainment, Luxury Brands, Energy and Tech/Robotics (AI) Stocks Added to Investorideas.com

New Biotech Stocks Added to Directory - $ABBV, $ISR, $MTP, $MBRX

Point Roberts, WA, Delta BC – April 7, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, mining, renewable energy, entertainment, luxury brands, and robotics- artificial intelligence.

The newest biotech companies include multiple companies involved in the treatment of cancers, with one, Midatech Pharma Plc (NasdaqCM:MTP) using gold nanoparticle technology.

Other new stocks within the sector this week are companies treating hypertension (PAH), muscular dystrophy and Alzheimer’s disease respectively.

Also included is a cross-over from the tech/robotics sector, Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS), a global technology leader in robotic-assisted vascular interventions, whose CorPath® System is the first FDA-cleared medical device to bring robotic precision to interventional procedures.

The latest mining stock additions are both Canadian Stock Exchange (CSE) listed companies, with one involved in gold mining operations and the other, EnviroLeach Technologies Inc. (CSE: ETI) offering a unique, cost-effective and environmentally friendly alternative for the extraction of precious metals.

EnviroLeach crosses into the greentech sector which is also adding ConEd (ED) due to its increasing commitment to energy efficiency and a bioenergy company that is developing a process to convert renewable resources into hydrocarbons through fermentation.

Canadian outerwear manufacturer Canada Goose Holdings Inc. (NYSE: GOOS; TSX: GOOS.TO) has been added to the luxury brands stock list and the CSE-Listed energy company Squatex Energy and Ressources Inc. (CSE:SQX) has been added to the Oil and Gas Stocks directory.

Rounding out this week’s additions is the entertainment stock Cinedigm (NasdaqGM: CIDM) which provides premium feature films and series to digital platforms including iTunes, Netflix, and Amazon; cable and satellite providers including Comcast, Dish Network and DirecTV; and major retailers including Walmart and Target.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

   

New Biotech Companies Added to Investorideas directory:

AbbVie Inc. (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

IsoRay, Inc. (NYSE MKT: ISR) designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer. Isoray Inc, through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.

Midatech Pharma Plc (NasdaqCM:MTP) is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a US commercial operation marketing four cancer care supportive products, and co-promoting two others. Midatech's strategy is to internally develop oncology products and collaborate with partners in other therapy areas, and to drive growth both organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies: Q-Sphera for sustained release and our proprietary gold nanoparticles.

Moleculin Biotech, Inc. (NasdaqCM: MBRX) is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, an anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two preclinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system. The other portfolio targets the metabolism of tumors.

SteadyMed Ltd. (NasdaqGM: STDY) is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel.

Summit Therapeutics plc (NasdaqGM:SMMT) is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection.

vTv Therapeutics Inc. (NasdaqGM: VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

New Mining Companies Added:

EnviroLeach Technologies Inc. (CSE: ETI) has developed a unique, cost-effective and environmentally friendly alternative to cyanide for the hydrometallurgical extraction of precious metals for the mining and E-waste sectors. The patent-pending EnviroLeach process is safe, eco-friendly, and provides comparable leach kinetics to high intensity cyanide on most ores, concentrates and tailings.

Miramont Resources Corp. (CSE:MONT) is engaged in the acquisition, exploration and development of mineral properties in Canada. Its current focus is to conduct the proposed exploration program on the Midas Gold Property, along with continuing to identify and potentially acquire additional property interests, assess their potential and engage in exploration activities.

New Renewable Energy Companies Added:

Consolidated Edison Inc. (NYSE: ED) subsidiary ConEdison Solutions is a leading energy services company that provides renewable energy, sustainability services, cost-effective energy efficiency solutions, demand response, and energy performance contracting. The company serves commercial, industrial, residential and government customers, as well as universities, public school districts, and hospitals nationwide. Offering innovative products, financial stability, and a commitment to customer service, the company has offices in Valhalla, New York; Burlington, Massachusetts; Cherry Hill, New Jersey; Falls Church, Virginia; Tampa, Florida; Overland Park, Kansas, Nashville, Tennessee; and Bloomington, Minnesota. The company's dedicated team of energy professionals delivers a broad range of energy solutions. Con Edison Solutions offers programs and services designed to help customers achieve their individual energy objectives and is accredited as an Energy Services Provider (ESP) by the National Association of Energy Service Companies (NAESCO).

Global Bioenergies (Paris: ALGBE) is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, operates an industrial pilot, has started operations at its demo plant in Germany, and is preparing its first full-scale plant through a joint venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry.

New Entertainment Companies Added:

Cinedigm (NasdaqGM: CIDM) powers custom content solutions to the world's largest retail, media and technology companies. We provide premium feature films and series to digital platforms including iTunes, Netflix, and Amazon, cable and satellite providers including Comcast, Dish Network and DirecTV, and major retailers including Walmart and Target. Leveraging Cinedigm's unique capabilities, content and technology, the Company has emerged as a leader in the fast-growing over-the-top channel business, with four channels under management that reach hundreds of millions of devices while also providing premium content and service expertise to the entire OTT ecosystem.

New Luxury Brand Companies Added:

Canada Goose Holdings Inc. (NYSE: GOOS; TSX: GOOS.TO) Founded in a small warehouse in Toronto, Canada 60 years ago, Canada Goose has grown into a global outerwear brand. Canada Goose is a designer, manufacturer, distributor and retailer of premium outerwear for men, women and children. The Company’s jackets are sold in 36 countries around the world, including in two owned retail stores and four e-commerce stores.

New Energy Companies Added:

Squatex Energy and Ressources Inc. (CSE:SQX) is a junior oil and gas exploration company established in 2001 which main activity is to carry out works and studies aiming at the evaluation and the development of the oil and gas potential of a territory of 656,093 hectares under exploration license in the Province of Québec, in which it is holding a 70% interest.

New Tech/Robotics – AI Companies Added:

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

Read this release in full at  

 http://www.investorideas.com/news/2017/biotech/04071Stocks.asp

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing: http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Positive Results from RepliCel’s (OTCQB: $REPCF; TSX: $RP.V) RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date

Positive Results from RepliCel’s (OTCQB: $REPCF; TSX: $RP.V) RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date

Interim trial results lead researchers to conclude that the injection of RCS-01 is not only very safe, but also has the potential to reverse effects of aging skin, representing a natural alternative to existing anti-aging treatments

VANCOUVER, BC – April 4, 2017 – (Investorideas.com Newswire) RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”) is pleased to report statistically and clinically significant positive data from the interim analysis of its phase I study evaluating RCS-01 for the treatment of aging and sun-damaged skin.

The primary objective of this trial was to establish a complete safety profile for intradermal injections of RCS-01 (RepliCel’s type 1 collagen-expressing, hair follicle-derived fibroblasts [“NBDS cells”]) at six months post-injection. Participants in the Germany-based study did not report any serious adverse events at the interim point of the trial. Researchers also gathered compelling positive proof-of-concept data indicating the product’s potential for skin rejuvenation.

The study was neither powered for, nor was expected to show statistically significant results of efficacy. However, the nearly two-fold increase in gene expression of collagen-related biomarkers in the skin, after a single injection of RCS-01, was so profound with a single RCS-01 injection, that the results are considered statistically significant. The study observed the impact of the injection on ten different biomarkers that, in peer-reviewed medical literature, are highly correlated with skin aging and chronically sun-damaged skin. Notably, gene expression markers, such as tissue inhibitor of metalloproteinases (TIMP), showed significant changes expected to correlate with increased collagen fibers. Increased collagen production, and reduced collagen degradation, is associated with fewer wrinkles and the repair of sun-damaged skin.

  

“This type of positive effect on TIMP gene expression, which is related to protection against collagen degeneration, is rarely observed. In my experience, after decades of performing these tests, this is an exceptional finding, particularly for a safety trial with a small sample size,” stated Prof. Dr. med Jean Krutmann, Scientific Manager of the IUF Leibniz Research Institute for Environmental Medicine where the study was conducted. “The promising results demonstrate the potential of RCS-01 to promote skin rejuvenation. An increase in collagen markers of this nature would be expected to translate into clinically measurable and aesthetically visible effects.”

Krutmann concluded: “Replication of these results in a larger trial would confirm our view of the product’s potential as a more natural alternative to Botulinum toxins and fillers that only temporarily prevent and reverse the signs of aging.”  

“This study not only showed an excellent safety profile, but also provides compelling proof-of-concept that RepliCel’s RCS-01 cells are, by nature, very good collagen producers in the skin,” stated Dr. Rolf Hoffmann, RepliCel’s Chief Medical Officer. “We are highly encouraged by the findings and eager to demonstrate the correlation between the change in these biomarkers and clinically important endpoints such as wrinkle depth, in a larger multi-centre trial studying optimal dose and treatment frequency.”

“As a practicing dermatologist,” Hoffmann continued, “the potential of RCS-01 represents a leap-forward in the way we look at skin anti-aging, especially for the fine wrinkles in UV-damaged skin where we have no long-lasting treatment today. Of importance is the fact that, because RCS-01 is comprised of cells derived from tissue at the back of the patient’s scalp, these cells are not only very good collagen producers, but also UV- protected and therefore more functionally active.”

“In my opinion,” Hoffmann concluded, “this is the first example of a treatment potentially capable of rejuvenating UV-damaged skin.”

“This is the most compelling data we have announced to date,” stated RepliCel CEO and President, R. Lee Buckler. “Longer term, this data is very complementary to our focus on commercializing a next-generation dermal injector and its targeted application not only with RCS-01, but also with other aesthetic products on the market today.  We look forward to discussing these findings and the potential of our products with a number of aesthetic-focused institutional investors and major multinational licensing partners who have already expressed interest in our programs.”

Read this release in full at http://www.investorideas.com/news/2017/biotech/04041REPCF.asp

About Aging and UV-damaged Skin Markets

Ultra-violet (UV) light exposure from the sun is responsible for up to 80% of visible facial skin aging. According to statistics from the American Society for Plastic Surgeons, $2.5 billion was spent on facial aesthetics in 2013 and this is predicted to grow to over $5.4 billion by 2020. Dermal filler procedures are growing over 15% annually.

About the RCS-01 Study

The clinical trial was a randomized, double-blind, placebo-controlled, single-centre, phase I safety study of intradermal injections of RCS-01 in healthy subjects. The primary endpoint was to assess the local safety profile by recording and evaluating adverse events reported at the treatment evaluation sites. Secondary safety measures related to any reporting of systemic adverse events and assessment of histopathological abnormalities of the treatment sites. Secondary endpoints also included evaluating any changes in expression of numerous genetic markers (using real-time PCR) related to intrinsic skin aging, skin wrinkling and solar degeneration of skin.  

After trial inclusion, all participants provided a biopsy from the scalp from which RCS-01 was prepared at a central GMP manufacturing site. Study participants were randomized to one of two treatment subgroups that received intradermal injections of either RCS-01 or placebo.  Each participant had four treatment evaluations sites identified on their buttocks, two on each side to allow for a within-subject comparison of single and triple injections of RCS-01 with placebo respectively. Participants in the RCS-01 Subgroup received injections of RCS-01 or placebo or a ‘sham’ injection (a needle penetration without injection of liquid). Participants in the Placebo Subgroup were randomized to receive only injections of placebo or sham injections to compare the systemic safety profile to the RCS Subgroup.

Baseline evaluations of subjects’ overall health and skin condition at treatment sites on their buttocks were performed before receipt of injections at Day 0. In addition to injections delivered at Day 0, the pre-selected treatment evaluation sites received intradermal injections of RCS-01 or placebo (cryomedium) or a sham injection four and eight weeks after Day 0 according to a randomization schedule for a total of three injections per treatment site.

All participants returned/will return to the clinic for at least nine visits to monitor safety. Assessment of the local safety profile was performed by the investigator before each injection visit, two to four days after injection, and 12 and 26 weeks after injection. The investigator was asked to examine each treatment site for the presence or absence of local adverse events and grade them with respect to relatedness to treatment, severity and seriousness. Other study assessments included recording of vital signs at each visit and routine laboratory assessments at screening, injection visits and at the Week 26 time point.  At the 12-week time point, nine randomly selected participants provided biopsies from all injection sites for gene expression analysis of skin markers related to aging. At Week-26 (cut-off date of the interim analysis), the remaining participants provided biopsies of all injection sites for histopathological analysis.

All reported pre-defined local adverse events related to injection or sham were transient and mainly mild in intensity only. No other related local or systemic adverse events were reported. No clinically relevant abnormal laboratory results or abnormal vital signs were reported up to the cut-off date of this interim analysis. Histopathological assessments of treatment evaluation site biopsies were all judged to be normal by a blinded investigator.

About Prof. Dr. med Jean Krutmann

Prof Dr. med Jean Krutmann is Professor of Dermatology and Environmental Medicine and Director of the IUF Leibniz Research Institute for Environmental Medicine at the Heinrich-Heine-University Düsseldorf. He is a coordinator of the Leibniz Research Alliance “Healthy Aging” (a strategic alliance of 23 Leibniz institutes). His research is in the field of derma-toxicology and immune-dermatology with special emphasis on environmentally-induced skin diseases and skin aging. Prof. Krutmann is author or co-author of more than 200 papers. He is the recipient of the International Arnold-Rikli-Award, the Albert Fleckenstein Award, the Paul Gerson Unna Award, the Oscar Gans Award, the C.E.R.I.E.S. Research Support Award and the Dermopharmacy Innovation Award. He is a visiting and adjunct professor of dermatology at the Nagoya City University, Japan, Case Western Case Western Reserve University, Cleveland, Ohio and University of Alabama, Birmingham, AL, USA. He is a member of the National Academy of Science of Germany and Xu Guang Qi Lecturer, Shanghai Institute for Biological Sciences (CAS), Shanghai, China.

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal tissue healing and function. The Company’s product pipeline is comprised of three clinical-stage products:  RCT-01 for tendon repair, RCS-01 for skin rejuvenation and RCH-01 for hair restoration. RCH-01 is under exclusive license by Shiseido Company for certain Asian countries. All product candidates are based on RepliCel’s innovative technology, utilizing cell populations isolated from a patient’s healthy hair follicles.

RepliCel is also developing a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications. Please visit http://replicel.com/ for additional information.

For more information, please contact:

Lee Buckler, CEO and President Telephone: 604-248-8693 / lee@replicel.com

Forward-looking information

Certain statements in this news release are forward-looking statements, which reflect the expectations of management regarding the results of the RCS-01 Phase 1 skin trial. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include: statements relating to the anti-aging potential of RCS-01, its ability to promote skin rejuvenation, and its potential as a more natural alternative to Botulinum toxins and fillers; the Company’s expectation that significant changes to gene expression markers are expected to correlate with increased collagen fibers; that increased collagen production and reduced collagen degradation should potentially lead to fewer wrinkles and the repair of sun-damaged skin; that RepliCel’s RCS-01 cells are by nature very good collagen producers in the skin; the potential correlation between changes in biomarkers and clinically important endpoints; that the potential of RCS-01 represents a leap-forward in skin anti-aging; the potential application for other aesthetic products; and the expected timing of return of trial participants for analysis and the process to be undertaken in connection with same. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking statements, including: the risk that there will be delays enrolling clinical trial participants; the risk that the Company will receive negative results from the Company’s clinical trials; the effects of government regulation on the Company’s business; risks associated with future approvals for clinical trials; risks associated with the Company obtaining approval for its clinical trial in Germany; risks associated with the Company obtaining all necessary regulatory approvals for its various programs in Canada, the USA and Germany; risks associated with the Company’s ability to obtain and protect rights to its intellectual property; risks and uncertainties in connection with the outstanding issues alleged by Shiseido in connection with the License and Co-development Agreement; risks and uncertainties associated with the Company’s ability to raise additional capital; and other factors beyond the Company’s control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2015 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at www.sec.gov and with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure – the following is a paid news release for RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP). Learn more about our newswire . pricing and how to publish your news- http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Investorideas.com Newswire now on News360 app

Investorideas.com Newswire now on News360 app

Point Roberts, WA, Delta BC – April 3,  2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces the Investorideas.com newswire is now live on the News360 app.
News360 app link for Investorideas.com newswire:  https://news360.com/p/investorideas
About News360 app https://news360.com/

•         Qualified Audience - 6M+ News360 users

•         Intelligent Engagement - Average CTR of 4%+ and 1+ minute time on page

•         Sticky Engagement - 30% of News360 sessions are longer than 10 minutes

Learn more about the Investorideas.com newswire and how to publish your news:

http://www.investorideas.com/News-Upload/

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

This Week’s Mining, Biotech, Sports, Gaming/Tech Stocks Added

This Week’s Mining, Biotech, Sports, Gaming/Tech Stocks Added

New Mining Stocks; $CUZ.V, $EGA.V, $PGOL

Point Roberts, WA, Delta BC – March 24, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in mining, biotech, and sports.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

New mining companies all operate within North America and are involved in cobalt, gold and silver respectively.  Also added is graphite mining company, Eagle Graphite Incorporated (TSX: EGA.V) which crossed over into the renewable energy stocks list.

Biotech companies include a pharmaceutical company developing a cure for HBV infection and a life sciences company that has also crossed into the cannabis stock list with its analytical devices and CBD/hemp oils and formulations.

The newest sports stock is Canlan Ice Sports Corp. (TSX: ICE.TO), the North American leader in the development, operation and ownership of multi-purpose recreation and entertainment facilities – including ice surfaces, soccer fields, sport, volleyball, and basketball courts.

Although not new to the tech list – Alibaba (NYSE: BABA) has now entered the gaming and social networking arena with UCWeb Inc. (UCWeb), a business within Alibaba Mobile Business Group, that in Russia is in partnership with Mail.ru Group and has plans to expand in mobile games collaboration.

New Mining Companies Added to Investorideas directory:

Cruz Cobalt Corp. (TSX: CUZ.V; OTC: BKTPF; FSE: A2AG5M) is a leader in cobalt exploration with significant projects across North America. Cruz Capital is actively engaged in acquiring and developing cobalt assets Globally. We have acquired numerous high-grade cobalt projects located in North America. Seven of the cobalt projects acquired are located in Canada while one is located in Idaho.

Eagle Graphite Incorporated (TSX: EGA.V; OTC: APMFF; FSE: NJGP;)  is an Ontario company that owns one of only two natural flake graphite production facilities in North America, located 35 kilometres west of the city of Nelson in British Columbia, Canada, and 70 kilometres north of the state of Washington, USA, known as the Black Crystal graphite quarry.

Patriot Gold Corp (OTC:PGOL) is a precious metals exploration and production company with the mission to discover and develop significant gold and silver assets in Arizona and Nevada. Patriot holds a 3% royalty in the Moss Mine in Arizona, a 30% interest in the Bruner gold project in Nevada, and a 100% interest in the Vernal and Windy Peak projects in Nevada.

New Biotech Companies Added:

Arbutus Biopharma Corporation (NasdaqGS:ABUS) is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Doylestown, PA.

CB Scientific (OTC:CBSC) through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, Medical Delivery Systems, laboratory services, personal analytical kits and devices and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific is continuing to develop new technologies specifically for cannabis (hemp) analytics. CB Scientific believes every product sold to patients as "Medical Quality" should be inspected for health benefits, safety, consistency, purity, potency and packaged properly for distribution. CB Scientific has worked with many of the cannabis industry leaders in the country and have also been featured in cannabis industry publications including High Times Magazine, Culture and many trade publications, on-air interviews and panel discussions across the United States. CB Scientific's focus has been the education and safety of consumers combined with innovation to put power into the hands of the patients.

New Sports Companies Added:

Canlan Ice Sports Corp. (TSX: ICE.TO) is the North American leader in the development, operations and ownership of multi-purpose recreation and entertainment facilities. We are the largest private sector owner and operator of recreation facilities in North America and currently own, lease and/or manage 20 facilities in Canada and the United States with 57 ice surfaces, as well as five indoor soccer fields, and 15 sport, volleyball, and basketball courts.

New Gaming-Tech Companies Added:

UCWeb Inc. (UCWeb), (NYSE:BABA) a business within Alibaba Mobile Business Group, is a leading provider of mobile internet software and services. Since the inception in 2004, UCWeb's mission has been to provide better mobile internet experience to people around the world. The international product portfolio of UCWeb includes UC Browser (mobile browsing service), UC News (content distributor), 9Apps (Android app store), and UC Union (mobile traffic and monetization platform). UC Browser is one of the world's top 3 mobile browsers (as per StatCounter). UC Browser has reached 420 million Monthly Active Users as of August 2016, while 9Apps has clocked over 250 million. Additional information about UCWeb and its products can be found at www.ucweb.com. GAMING: Alibaba Games also upgrades the traffic distribution by integrating the traffic in both the iOS and Android platforms. The company is using big data technology for accurate distribution and precise recommendation system to each user. More previously in Russia UCWeb, an Alibaba Digital Media & Entertainment Group company disclosed its partnership with Mail.ru Group and the plan to expand in mobile games collaboration. Now with the establishment of the "Global Strategic Alliance of Game Distribution" that Alibaba Digital Media & Entertainment is seeing more in-depth cooperation with the local giant in Russia market.

Read this release in full at http://www.investorideas.com/news/2017/mining/03241Stocks.asp

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing : http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411